Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Senior Vice President | February 29, 2012 | March 02, 2012 |
| MARAVAI LIFESCIENCES HOLDINGS, INC.MRVI · Entity 4291 | Director | November 19, 2021 | November 23, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date February 29, 2012 · Filed March 02, 2012
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 144,311 |
Ending reported balance
After 2012-03-01 transaction · row 24
24 source rows · reconciled sequenceRow 1 · 2012-02-29 · Sale · Disposed 4,900 · Balance 220,896 Row 2 · 2012-02-29 · Sale · Disposed 5,750 · Balance 215,146 Row 3 · 2012-02-29 · Sale · Disposed 700 · Balance 214,446 Row 4 · 2012-02-29 · Sale · Disposed 4,115 · Balance 210,331 Row 5 · 2012-02-29 · Sale · Disposed 200 · Balance 210,131 Row 6 · 2012-02-29 · Sale · Disposed 15,135 · Balance 194,996 Row 7 · 2012-02-29 · Sale · Disposed 12,318 · Balance 182,678 Row 8 · 2012-02-29 · Sale · Disposed 2,800 · Balance 179,878 Row 9 · 2012-02-29 · Sale · Disposed 2,300 · Balance 177,578 Row 10 · 2012-02-29 · Sale · Disposed 4,403 · Balance 173,175 Row 11 · 2012-02-29 · Sale · Disposed 200 · Balance 172,975 Row 12 · 2012-02-29 · Sale · Disposed 3,697 · Balance 169,278 Row 13 · 2012-02-29 · Sale · Disposed 2,200 · Balance 167,078 Row 14 · 2012-02-29 · Sale · Disposed 100 · Balance 166,978 Row 15 · 2012-02-29 · Sale · Disposed 1,560 · Balance 165,418 Row 16 · 2012-02-29 · Sale · Disposed 100 · Balance 165,318 Row 17 · 2012-02-29 · Sale · Disposed 100 · Balance 165,218 Row 18 · 2012-02-29 · Sale · Disposed 4,300 · Balance 160,918 Row 19 · 2012-02-29 · Sale · Disposed 700 · Balance 160,218 Row 20 · 2012-02-29 · Sale · Disposed 907 · Balance 159,311 Row 21 · 2012-03-01 · Sale · Disposed 3,737 · Balance 155,574 Row 22 · 2012-03-01 · Sale · Disposed 7,000 · Balance 148,574 Row 23 · 2012-03-01 · Sale · Disposed 100 · Balance 148,474 Row 24 · 2012-03-01 · Sale · Disposed 4,163 · Balance 144,311 |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 6,660 |
Reported balance
Holding disclosure · report date 2012-02-29 · row 25
Holding and transaction disclosures are not merged.
1 source rowRow 25 · Balance 6,660 F1: Balance in the Abbott Laboratories Stock Retirement Trust as of February 28, 2012. |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy wife | 20,400 |
Reported balance
Holding disclosure · report date 2012-02-29 · row 26
Holding and transaction disclosures are not merged.
1 source rowRow 26 · Balance 20,400 F2: The reporting person disclaims beneficial ownership of all securities held by his wife and daughters. |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy daughter | 250 |
Reported balance
Holding disclosure · report date 2012-02-29 · row 27
Holding and transaction disclosures are not merged.
1 source rowRow 27 · Balance 250 F2: The reporting person disclaims beneficial ownership of all securities held by his wife and daughters. |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy daughter | 250 |
Reported balance
Holding disclosure · report date 2012-02-29 · row 28
Holding and transaction disclosures are not merged.
1 source rowRow 28 · Balance 250 F2: The reporting person disclaims beneficial ownership of all securities held by his wife and daughters. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the Abbott Laboratories Stock Retirement Trust as of February 28, 2012.
F2: The reporting person disclaims beneficial ownership of all securities held by his wife and daughters.
MARAVAI LIFESCIENCES HOLDINGS, INC.
Report date November 19, 2021 · Filed November 23, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 26,123 |
Reported balance
After 2021-11-19 transaction · row 1
1 source rowRow 1 · 2021-11-19 · Grant · Acquired 4,271 · Balance 26,123 F1: Represents restricted stock units ("RSUs") granted on November 19, 2021, which vest in full one year from the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") granted on November 19, 2021, which vest in full one year from the date of the grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 19, 2021 Filed Nov 23, 2021 16:16 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantClass A Common Stock | 4,271 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-045777 · doc4.xml · nonDerivative · entry 1 Hance Robert B · CIK 0001383841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,123 F1 · shares: Represents restricted stock units ("RSUs") granted on November 19, 2021, which vest in full one year from the date of the grant. Read SEC document |
| November 24, 2020 Filed Nov 25, 2020 19:54 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | PurchaseClass A Common Stock | 10,000 | $27.00 | $270,000.00 |
DisclosureSEC source: 0000899243-20-032220 · doc4.xml · nonDerivative · entry 1 Hance Robert B · CIK 0001383841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,852 Read SEC document |
| November 19, 2020 Filed Nov 23, 2020 17:27 UTC | MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI · Entity 4291 | GrantClass A Common Stock | 11,852 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-031934 · doc4.xml · nonDerivative · entry 1 Hance Robert B · CIK 0001383841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,852 Read SEC document |
| March 01, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,163 | $57.05 | $237,503.31 |
DisclosureSEC source: 0001179110-12-004066 · edgar.xml · nonDerivative · entry 24 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,311 Read SEC document |
| March 01, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $57.05 | $5,705.02 |
DisclosureSEC source: 0001179110-12-004066 · edgar.xml · nonDerivative · entry 23 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,474 Read SEC document |
| March 01, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 7,000 | $57.05 | $399,350.00 |
DisclosureSEC source: 0001179110-12-004066 · edgar.xml · nonDerivative · entry 22 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,574 Read SEC document |
| March 01, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,737 | $57.06 | $213,233.22 |
DisclosureSEC source: 0001179110-12-004066 · edgar.xml · nonDerivative · entry 21 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,574 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 1,776 | $0.00 Strike: $57.04 | $0.00 |
DisclosureSEC source: 0001179110-12-004065 · edgar.xml · derivative · entry 33 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,776 Underlying: Common shares · 1,776 shares Expires 2013-02-13 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 3,050 | $0.00 Strike: $33.23 | $0.00 |
DisclosureSEC source: 0001179110-12-004065 · edgar.xml · derivative · entry 32 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 3,050 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 47,547 | $0.00 Strike: $51.91 | $0.00 |
DisclosureSEC source: 0001179110-12-004065 · edgar.xml · derivative · entry 31 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 47,547 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 26,000 | $0.00 Strike: $48.76 | $0.00 |
DisclosureSEC source: 0001179110-12-004065 · edgar.xml · derivative · entry 30 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 26,000 shares Expires 2016-12-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 57,000 | $0.00 Strike: $44.16 | $0.00 |
DisclosureSEC source: 0001179110-12-004065 · edgar.xml · derivative · entry 29 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 57,000 shares Expires 2016-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 46,400 | $0.00 Strike: $46.34 | $0.00 |
DisclosureSEC source: 0001179110-12-004065 · edgar.xml · derivative · entry 28 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 46,400 shares Expires 2015-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 9,900 | $56.77 | $562,023.00 |
DisclosureSEC source: 0001179110-12-004065 · edgar.xml · nonDerivative · entry 27 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,796 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 5,100 | $56.77 | $289,501.50 |
DisclosureSEC source: 0001179110-12-004065 · edgar.xml · nonDerivative · entry 26 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,696 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 6,176 | $56.76 | $350,549.76 |
DisclosureSEC source: 0001179110-12-004065 · edgar.xml · nonDerivative · entry 25 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,796 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $56.76 | $11,351.00 |
DisclosureSEC source: 0001179110-12-004065 · edgar.xml · nonDerivative · entry 24 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,972 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $56.75 | $5,675.25 |
DisclosureSEC source: 0001179110-12-004065 · edgar.xml · nonDerivative · entry 23 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,172 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 6,500 | $56.75 | $368,875.00 |
DisclosureSEC source: 0001179110-12-004065 · edgar.xml · nonDerivative · entry 22 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,272 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 400 | $56.75 | $22,699.60 |
DisclosureSEC source: 0001179110-12-004065 · edgar.xml · nonDerivative · entry 21 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,772 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 7,627 | $56.75 | $432,794.12 |
DisclosureSEC source: 0001179110-12-004065 · edgar.xml · nonDerivative · entry 20 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,172 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 7,450 | $56.74 | $422,713.00 |
DisclosureSEC source: 0001179110-12-004065 · edgar.xml · nonDerivative · entry 19 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,799 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 8,600 | $56.74 | $487,921.00 |
DisclosureSEC source: 0001179110-12-004065 · edgar.xml · nonDerivative · entry 18 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269,249 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 6,550 | $56.73 | $371,581.50 |
DisclosureSEC source: 0001179110-12-004065 · edgar.xml · nonDerivative · entry 17 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,849 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 900 | $56.73 | $51,052.50 |
DisclosureSEC source: 0001179110-12-004065 · edgar.xml · nonDerivative · entry 16 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,399 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,112 | $56.72 | $233,232.64 |
DisclosureSEC source: 0001179110-12-004065 · edgar.xml · nonDerivative · entry 15 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,299 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 400 | $56.72 | $22,686.00 |
DisclosureSEC source: 0001179110-12-004065 · edgar.xml · nonDerivative · entry 14 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,411 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 227 | $56.71 | $12,873.74 |
DisclosureSEC source: 0001179110-12-004065 · edgar.xml · nonDerivative · entry 13 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,811 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 5,873 | $56.71 | $333,057.83 |
DisclosureSEC source: 0001179110-12-004065 · edgar.xml · nonDerivative · entry 12 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,038 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $56.71 | $5,670.90 |
DisclosureSEC source: 0001179110-12-004065 · edgar.xml · nonDerivative · entry 11 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,911 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 18,100 | $56.71 | $1,026,360.50 |
DisclosureSEC source: 0001179110-12-004065 · edgar.xml · nonDerivative · entry 10 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,011 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 373 | $56.70 | $21,150.03 |
DisclosureSEC source: 0001179110-12-004065 · edgar.xml · nonDerivative · entry 9 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,111 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 6,300 | $56.70 | $357,210.00 |
DisclosureSEC source: 0001179110-12-004065 · edgar.xml · nonDerivative · entry 8 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,484 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 10,133 | $57.04 | $577,986.32 |
DisclosureSEC source: 0001179110-12-004065 · edgar.xml · nonDerivative · entry 7 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,784 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,776 | $57.04 | $101,303.04 |
DisclosureSEC source: 0001179110-12-004065 · edgar.xml · nonDerivative · entry 6 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,917 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 3,050 | $33.23 | $101,355.77 |
DisclosureSEC source: 0001179110-12-004065 · edgar.xml · nonDerivative · entry 5 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,693 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 47,547 | $51.91 | $2,468,164.77 |
DisclosureSEC source: 0001179110-12-004065 · edgar.xml · nonDerivative · entry 4 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,643 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 26,000 | $48.76 | $1,267,760.00 |
DisclosureSEC source: 0001179110-12-004065 · edgar.xml · nonDerivative · entry 3 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,096 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 57,000 | $44.16 | $2,517,120.00 |
DisclosureSEC source: 0001179110-12-004065 · edgar.xml · nonDerivative · entry 2 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,096 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 46,400 | $46.34 | $2,150,176.00 |
DisclosureSEC source: 0001179110-12-004065 · edgar.xml · nonDerivative · entry 1 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,096 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 907 | $56.72 | $51,447.76 |
DisclosureSEC source: 0001179110-12-004066 · edgar.xml · nonDerivative · entry 20 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,311 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 700 | $56.87 | $39,809.00 |
DisclosureSEC source: 0001179110-12-004066 · edgar.xml · nonDerivative · entry 19 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,218 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,300 | $56.87 | $244,519.50 |
DisclosureSEC source: 0001179110-12-004066 · edgar.xml · nonDerivative · entry 18 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,918 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $56.86 | $5,686.25 |
DisclosureSEC source: 0001179110-12-004066 · edgar.xml · nonDerivative · entry 17 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,218 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $56.86 | $5,686.00 |
DisclosureSEC source: 0001179110-12-004066 · edgar.xml · nonDerivative · entry 16 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,318 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,560 | $56.85 | $88,686.00 |
DisclosureSEC source: 0001179110-12-004066 · edgar.xml · nonDerivative · entry 15 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,418 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $56.85 | $5,684.50 |
DisclosureSEC source: 0001179110-12-004066 · edgar.xml · nonDerivative · entry 14 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,978 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,200 | $56.84 | $125,048.00 |
DisclosureSEC source: 0001179110-12-004066 · edgar.xml · nonDerivative · entry 13 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,078 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,697 | $56.83 | $210,100.51 |
DisclosureSEC source: 0001179110-12-004066 · edgar.xml · nonDerivative · entry 12 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,278 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $56.83 | $11,365.00 |
DisclosureSEC source: 0001179110-12-004066 · edgar.xml · nonDerivative · entry 11 Hance Robert B · CIK 0001383841 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,975 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.